StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Pacira BioSciences's total debt was $363.12M at Jun 30, 2026. For fiscal 2025 it was $372.19M, down 36.4% from the year before. The highest annual figure on record is $585.32M in fiscal 2024.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$372.19M-36.4%
FY2024Dec 31, 2024$585.32M+393.8%
FY2016Dec 31, 2016$118.53M-0.0%
FY2015Dec 31, 2015$118.53M-1.2%
FY2014Dec 31, 2014$120.00M0.0%
FY2013Dec 31, 2013$120.00M+376.4%
FY2012Dec 31, 2012$25.19M-1.5%
FY2011Dec 31, 2011$25.58M+2.1%
FY2010Dec 31, 2010$25.05M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$363.12M-38.0%
Q1 FY2026Mar 31, 2026$367.66M+210.2%
Q4 FY2025Dec 31, 2025$372.19M–
Q3 FY2025Sep 30, 2025$376.72M–
Q4 FY2024Dec 31, 2024$585.32M–
Q4 FY2016Dec 31, 2016$118.53M–

More Pacira BioSciences figures

See a number that looks wrong?